C-Path Welcomes BioCentury Inc. Co-Founder Bernstein to Board of Directors
Dr. Bernstein will help steer the strategic vision of C-Path as the organization’s newest board member
TUCSON, Ariz., March 14, 2023 — Critical Path Institute (C-Path) today announced the appointment of Karen Bernstein, Ph.D., to its Board of Directors. Bernstein will help steer the strategic vision and mission of the nonprofit organization as it continues to accelerate the path to a healthier world.
Bernstein is co-founder and chairman of BioCentury Inc. and was Editor-in-Chief from October 1992 to August 2012. She is currently on the Board of Directors at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain, and at Codiak BioSciences Inc., which is pioneering exosome research and development to create an entirely new class of medicines — exosome therapeutics. Bernstein is on the board of trustees of the Keck Graduate Institute. She serves on the board of overseers of Scripps Research and on the board of Mind What Matters, a nonprofit that provides support for Alzheimer’s family caregivers.
“Karen’s years of experience in the industry, particularly in drug development for orphan diseases and exosome research, make her a perfect addition to the C-Path board and organization,” said Wainwright Fishburn, C-Path Board Chair. “We look forward to adding her input and breadth of experience to the Board of Directors as we continue to grow as a global organization and accelerate the development of treatments and cures for patients across the world.”
Bernstein holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council.
“I am excited to be joining the Board of C-Path. Its mission of improving the drug development process through collaborations between government regulatory and research agencies, biopharmaceutical companies, patient organizations and academia is one that I have strongly advocated for throughout my 36-year career in the industry,” said Bernstein. “I look forward to the opportunity to truly make a difference in how drugs are developed.”
Her notable honors include being inducted into the Biotechnology Hall of Fame, citing her lifetime contribution to the biotech community and receiving a Special Recognition award at the American Liver Foundation’s Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, Bernstein was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. She was also named Commentator of the Year by the European Mediscience Awards in 2016.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona, C-Path in Europe is headquartered in Amsterdam, Netherlands and C-Path Ltd. operates from Dublin, Ireland with additional staff in multiple other locations. For more information, visit c-path.org.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250, and 45% funded by non-government source(s), totaling $14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.